Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Uterine Neoplasms 1 Uterine Diseases 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Uterine Cervical Diseases 1 Urogenital Neoplasms 1 Urogenital Diseases 1 Precancerous Conditions 1 Neuroblastoma 1 Neoplasms by Site 1 Lung Neoplasms 1 Genital Neoplasms, Female 1 Genital Diseases, Female 1 Genital Diseases 1 Female Urogenital Diseases and Pregnancy Complications 1

Interventions

pembrolizumab 91 Carboplatin 79 Specimen Handling 76 Magnetic Resonance Spectroscopy 64 Pemetrexed 60 Cisplatin 49 durvalumab 44 Paclitaxel 38 Nivolumab 34 atezolizumab 32 Radiotherapy 30 Radiosurgery 30 osimertinib 29 Blood Specimen Collection 27 Biopsy 26 Gemcitabine 24 Docetaxel 24 Immunoglobulin G 23 Standard of Care 22 Disulfides 22 Etoposide 21 Drug Therapy 21 Taxes 18 Practice Guidelines as Topic 18 Radiation 17 Educational Status 16 130-nm albumin-bound paclitaxel 15 X-Rays 14 Surveys and Questionnaires 14 Bevacizumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × Pregnancy Tests × 1 year × Clear all

NCT06620835 2026-04-29

OPTALK

Groupe Francais De Pneumo-Cancerologie

Phase 2 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡